GO
Loading...

Amgen Inc

More

  • Early Glance: Biotechnology companies Wednesday, 18 Feb 2015 | 10:53 AM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $154.66. Biogen Idec rose$. 22 or. 1 percent, to $398.13. Celgene Corp. rose$. 99 or. 9 percent, to $117.31.

  • Final Glance: Biotechnology companies Tuesday, 17 Feb 2015 | 6:09 PM ET

    Amgen Inc. rose$. 76 or. 5 percent, to $154.24. Biogen Idec rose $6.25 or 1.6 percent, to $397.91. Celgene Corp. rose$. 44 or. 4 percent, to $116.32.

  • Midday Glance: Biotechnology companies Tuesday, 17 Feb 2015 | 1:31 PM ET

    Amgen Inc. rose$. 40 or. 3 percent, to $153.88. Biogen Idec rose $7.63 or 1.9 percent, to $399.29. Celgene Corp. rose$. 19 or. 2 percent, to $116.07.

  • Feb 17- CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place." CVS' call for cost controls follows sharp criticism from insurers, other payers and...

  • Early Glance: Biotechnology companies Tuesday, 17 Feb 2015 | 11:00 AM ET

    Amgen Inc. rose $1.17 or. 8 percent, to $154.65. Biogen Idec rose $4.34 or 1.1 percent, to $396.00. Celgene Corp. rose$. 95 or. 8 percent, to $116.83.

  • Feb 5- Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectible drugs and biosimilars, or copies of biotech drugs. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira soared 35 percent to near $88 before the bell Thursday, while Pfizer was up 3.6...

  • Obama seeks $215 million for 'precision medicine' Friday, 30 Jan 2015 | 6:00 AM ET
    President Barack Obama delivers the State of the Union address on January 20, 2015 in the House Chamber of the U.S. Capitol in Washington.

    President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.

  • *Sanofi struggling to find new CEO in narrow field. PARIS, Jan 30- Barring a last-minute breakthrough, drugs firm Sanofi's Chairman Serge Weinberg may have to acknowledge in his results presentation next week that the hunt for a new chief executive is not going well. Paris- schooled Olivier Bohuon, chief executive of British medical devices maker Smith& Nephew,...

  • Early movers: AAPL, BA, GD, T, AMGN, EA & more Wednesday, 28 Jan 2015 | 8:01 AM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Jan 27- Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit, driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel and a tax credit. Despite pressure on overseas sales from the strong dollar that has put a crimp in pharmaceutical company profits, Amgen reiterated the 2015 forecast it provided in October for...

  • After-hours buzz: AT&T, Apple, Yahoo & more Tuesday, 27 Jan 2015 | 5:00 PM ET

    Companies making headlines after the bell Tuesday: AT&T, Apple, Yahoo & more.

  • Jan 27- Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit, driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel, cost cutting and a tax credit. The world's largest biotechnology company posted a net profit of $1.29 billion, or $1.68 per share, compared with a profit of $1.02 billion, or $1.33 per share, a year ago.

  • Dow futures off nearly 300 points after data miss Tuesday, 27 Jan 2015 | 9:05 AM ET
    A line of snow plows prepares to battle the blizzard on Lexington Ave in New York City on Jan. 26, 2015.

    U.S. stock index futures signaled a sharply lower open as major U.S. corporates missed fourth quarter earnings expectations.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • This measure says stocks are really cheap…maybe Thursday, 22 Jan 2015 | 12:26 PM ET
    Traders on the floor of the New York Stock Exchange.

    One valuation measure has sparked a debate among strategists as to whether the stock market is really, really cheap.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET

    Here are the fund managers Morningstar considers the best of the best.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...